Compare
Autolus Therapeutics plc vs Recursion Pharmaceuticals, Inc. vs Black Diamond Therapeutics, Inc. vs MeiraGTx Holdings plc
| Latest fiscal year | Autolus Therapeutics plc AUTL | Recursion Pharmaceuticals, Inc. RXRX | Black Diamond Therapeutics, Inc. BDTX | MeiraGTx Holdings plc MGTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $75.39M | $74.68M | $70.00M | $81.39M |
| Revenue growth (YoY) | +644.9% | +26.9% | n/a | +144.6% |
| Gross margin | -27.8% (computed) | 5.0% (computed) | n/a | n/a |
| Operating margin | -358.9% | -867.9% | 17.9% | -130.2% |
| Net margin | -381.4% | -863.4% | 32.0% | -140.3% |
| Net income | -$287.53M | -$644.76M | $22.37M | -$114.20M |
| EPS (Diluted) | -$1.08 | -$1.44 | $0.39 | -$1.42 |
| Operating cash flow | -$283.57M | -$371.81M | $29.61M | -$46.36M |
| Free cash flow | -$302.61M | -$378.28M | n/a | -$50.19M |
| Cash & equivalents | $104.13M | $743.29M | $20.99M | $65.93M |
| Total assets | $589.07M | $1.47B | $143.01M | $244.43M |
| Total liabilities | $410.94M | $343.26M | $30.80M | $250.22M |
| Shareholders' equity | $178.13M | $1.13B | $112.21M | -$5.79M |
| Return on year-end equity | -161.4% | -57.0% | 19.9% | n/a |
| Shares outstanding | n/a | 528.18M | 57.14M | 81.12M |
Revenue, most recent five fiscal years
| Fiscal year | Autolus Therapeutics plc | Recursion Pharmaceuticals, Inc. | Black Diamond Therapeutics, Inc. | MeiraGTx Holdings plc |
|---|---|---|---|---|
| Latest | $75.39M Ended 2025-12-31 | $74.68M Ended 2025-12-31 | $70.00M Ended 2025-12-31 | $81.39M Ended 2025-12-31 |
| 1 year earlier | $10.12M Ended 2024-12-31 | $58.84M Ended 2024-12-31 | $0 Ended 2024-12-31 | $33.28M Ended 2024-12-31 |
| 2 years earlier | $1.70M Ended 2023-12-31 | $44.58M Ended 2023-12-31 | n/a | $14.02M Ended 2023-12-31 |
| 3 years earlier | n/a | $39.84M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $10.18M Ended 2021-12-31 | n/a | n/a |